Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Ciceri, Fabio  [Clear All Filters]
2023
Bove C, Arcangeli S, Falcone L, Camisa B, Khoury REl, Greco B, De Lucia A, Bergamini A, Bondanza A, Ciceri F, et al. CD4 CAR-T cells targeting CD19 play a key role in exacerbating cytokine release syndrome, while maintaining long-term responses. J Immunother Cancer. 2023;11(1).
Passweg JR, Baldomero H, Ciceri F, Corbacioglu S, de la Camara R, Dolstra H, Glass B, Greco R, McLornan DP, Neven B, et al. Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey. Bone Marrow Transplant. 2023.
Naldini MMaria, Casirati G, Barcella M, Rancoita PMaria Vitt, Cosentino A, Caserta C, Pavesi F, Zonari E, Desantis G, Gilioli D, et al. Longitudinal single-cell profiling of chemotherapy response in acute myeloid leukemia. Nat Commun. 2023;14(1):1285.
Genchi A, Brambilla E, Sangalli F, Radaelli M, Bacigaluppi M, Furlan R, Andolfo A, Drago D, Magagnotti C, Scotti GMaria, et al. Neural stem cell transplantation in patients with progressive multiple sclerosis: an open-label, phase 1 study. Nat Med. 2023.
Yakoub-Agha I, Greco R, Onida F, de la Camara R, Ciceri F, Corbacioglu S, Dolstra H, Glass B, Kenyon M, McLornan DP, et al. Practice harmonization workshops of EBMT: an expert-based approach to generate practical and contemporary guidelines within the arena of hematopoietic cell transplantation and cellular therapy. Bone Marrow Transplant. 2023.
2022
Tokaz MC, Baldomero H, Cowan AJ, Saber W, Greinix H, Koh MBc, Kröger N, Mohty M, Galeano S, Okamoto S, et al. An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia. Transplant Cell Ther. 2022.
Ruggeri A, Galimard J-E, Labopin M, Rafii H, Blaise D, Ciceri F, Diez-Martin J-L, Cornelissen J, Chevallier P, Sanchez-Guijo F, et al. Comparison of outcomes after unrelated double-unit cord blood and haploidentical peripheral blood stem cell transplantation in adults with acute myeloid leukemia, a study on behalf of Eurocord and ALWP-EBMT. Transplant Cell Ther. 2022.
Ruggiero E, Carnevale E, Prodeus A, Magnani ZIrene, Camisa B, Merelli I, Politano C, Stasi L, Potenza A, Cianciotti BClaudia, et al. CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function. Sci Transl Med. 2022;14(631):eabg8027.
Greco B, Malacarne V, De Girardi F, Scotti GMaria, Manfredi F, Angelino E, Sirini C, Camisa B, Falcone L, Moresco MAngiola, et al. Disrupting N-glycan expression on tumor cells boosts chimeric antigen receptor T cell efficacy against solid malignancies. Sci Transl Med. 2022;14(628):eabg3072.
Del Fante C, Masiello F, Vaglio S, Lombardini L, Coluzzi S, Rondinelli MB, Ciceri F, Pupella S, De Angelis V. A survey on preoperative autologous blood donation policy in bone marrow stem cell donors in Italy. Blood Transfus. 2022.
2021
Shouval R, Fein JA, Labopin M, Cho C, Bazarbachi A, Baron F, Bug G, Ciceri F, Corbacioglu S, Galimard J-E, et al. Development and validation of a disease risk stratification system for patients with haematological malignancies: a retrospective cohort study of the European Society for Blood and Marrow Transplantation registry. Lancet Haematol. 2021;8(3):e205-e215.
Malagola M, Polverelli N, Rubini V, Martino M, Patriarca F, Bruno B, Giaccone L, Grillo G, Bramanti S, Bernasconi P, et al. GITMO REGISTRY STUDY ON ALLOGENEIC TRANSPLANTATION IN PATIENTS AGED OVER 60 FROM 2000 TO 2017. IMPROVEMENTS AND CRITICISMS. Transplant Cell Ther. 2021.
Nagler A, Labopin M, Dholaria B, Wu D, Choi G, Aljurf M, Ciceri F, Gedde-Dahl T, Meijer E, Niittyvuopio R, et al. Graft-Versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide versus Cyclosporine A and Methotrexate in Matched Sibling Donor Transplantation. Transplant Cell Ther. 2021.
Gentner B, Tucci F, Galimberti S, Fumagalli F, De Pellegrin M, Silvani P, Camesasca C, Pontesilli S, Darin S, Ciotti F, et al. Hematopoietic Stem- and Progenitor-Cell Gene Therapy for Hurler Syndrome. N Engl J Med. 2021;385(21):1929-1940.
Clerici D, Oltolini C, Greco R, Ripa M, Giglio F, Mastaglio S, Lorentino F, Pavesi F, Farina F, Liberatore C, et al. The place in therapy of ceftazidime/avibactam and ceftolozane/tazobactam in hematological patients with febrile neutropenia. Int J Antimicrob Agents. 2021:106335.
Greco R, Lorentino F, Albanese S, Stanghellini MTeresa Lup, Giglio F, Piemontese S, Clerici D, Lazzari L, Marcatti M, Mastaglio S, et al. Post-Transplant Cyclophosphamide and Sirolimus based Graft-versus-Host-Disease Prophylaxis in Allogeneic Stem Cell Transplant. Transplant Cell Ther. 2021.
Sahebi F, Eikema D-J, Koster L, Kröger N, Meijer E, van Doesum JA, Rovira M, Koc Y, Angelucci E, Blaise D, et al. Post-Transplant Cyclophosphamide for Graft vs Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type: A Study from the Chronic Malignancies Working Party of the EBM. Transplant Cell Ther. 2021.
Xue E, Lorentino F, Pavesi F, Assanelli A, Peccatori J, Bernardi M, Corti C, Ciceri F, Stanghellini MTeresa Lup. Ruxolitinib for chronic steroid-refractory graft versus host disease: a single center experience. Leuk Res. 2021;109:106642.
Kharfan-Dabaja MA, Labopin M, Brissot E, Kröger N, Finke J, Ciceri F, Deconinck E, Blaise D, Chevallier P, Gramatzki M, et al. Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia. Br J Haematol. 2021.
Lupo-Stanghellini MTeresa, Piemontese S, Assanelli A, Serpenti F, Mastaglio S, Clerici D, Giglio F, Greco R, Lorentino F, Pavesi F, et al. Second Solid Cancers After Hematopoietic Stem Cell Transplantation: Active Surveillance During Long-term Follow-up. Hemasphere. 2021;5(11):e654.
2020
Oltolini C, Piemontese S, Ripa M, Greco R, Nozza S, Corti C, Peccatori J, Scarpellini P, Ciceri F, Castagna A. Allogeneic bone marrow transplantation in HIV people with hematological malignancies: post-transplant cyclophosphamide to overcome the HLA-matching barrier. Transpl Infect Dis. 2020:e13551.
Maffini E, Labopin M, Blaise D, Ciceri F, Gulbas Z, Deconinck E, Leblond V, Chevallier P, Socié G, Araujo MColorado, et al. CD34+ cell dose effects on clinical outcomes after T-cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem cells. A Study from the Acute Leukemia Working Party of the European. Am J Hematol. 2020.
Mastellos DC, da Silva BGPPires, Fonseca BAL, Fonseca NP, Martins MA, Mastaglio S, Ruggeri A, Sironi M, Radermacher P, Chrysanthopoulou A, et al. Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy. Clin Immunol. 2020:108598.
Bazarbachi A, Labopin M, Angelucci E, Gulbas Z, Ozdoğu H, Arat M, de Rosa L, Pastano R, Pioltelli P, Montserrat R, et al. Haploidentical transplant with post-transplant cyclophosphamide for T-cell acute lymphoblastic leukemia: a report from the EBMT acute leukemia working party. Biol Blood Marrow Transplant. 2020.
Oltolini C, Greco R, Galli L, Clerici D, Lorentino F, Xue E, Stanghellini MTeresa Lup, Giglio F, Uhr L, Ripa M, et al. Infections after allogenic transplant with post-transplant cyclophosphamide: impact of donor HLA-matching. Biol Blood Marrow Transplant. 2020.

Pages